Methyl gallate and hyaluronic acid-nanoconjugate targeting HSP90β for osteoarthritis therapy - PubMed
4 days ago
- #Osteoarthritis
- #HSP90β
- #Nanoconjugate
- Methyl gallate (MG) delays osteoarthritis (OA) progression by reducing cartilage inflammation and degeneration.
- HSP90β identified as a key target of MG in chondrocytes through various assays.
- Positive correlation found between HSP90β expression and cartilage degeneration in OA rat models.
- Clinical analysis of 53 OA patients links HSP90β expression to pain scores.
- Silencing HSP90β in rat chondrocytes reduces mRNA levels of matrix metalloproteinases and IL-6, and decreases PI3K/Akt pathway-related proteins.
- MG conjugated to hyaluronic acid (HA) via a reduction-responsive disulfide linker enhances therapeutic efficacy in OA mouse models.
- HA-MG shows increased accumulation and retention in the joint cavity, improving OA therapy.